Can upadacitinib be prescribed to a patient who is currently taking Femoston (estradiol‑norethisterone acetate) hormone replacement therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can Upadacitinib Be Given While on Femostan?

Upadacitinib can be prescribed to patients taking Femostan (estradiol-norethisterone), but this combination requires heightened caution due to significantly increased venous thromboembolism (VTE) risk from both medications.

Critical Safety Concern: Venous Thromboembolism Risk

The primary concern with this combination is additive VTE risk. Both hormone replacement therapy (HRT) and JAK inhibitors independently increase thrombotic risk, and their combination creates a high-risk scenario.

Evidence from Guidelines

EULAR 2020 guidelines explicitly identify hormone replacement therapy as a VTE risk factor when using JAK inhibitors 1. The guidelines state: "VTEs are seen especially in patients with a high risk for these events...such as those with a previous history of thromboembolic events, those with high body mass index, those with hormone replacement therapy and higher age. Therefore, JAKi should be used with caution in patients with high risk of TE events" 1.

FDA Drug Label Warnings

The FDA-approved upadacitinib label includes warnings about thrombosis risk 2. While the label doesn't explicitly contraindicate HRT use, venous thrombosis events were documented in clinical trials, with rates of 0.5 per 100 patient-years for the 15 mg dose 2.

Risk Stratification Algorithm

Assess the following VTE risk factors:

  • Age ≥65 years - Major risk factor
  • Previous VTE history - Absolute contraindication to combination
  • High BMI/obesity - Significant risk factor
  • Current smoking or long-term smoking history - Major risk factor
  • Cardiovascular disease history - Significant risk factor
  • Immobility or recent surgery - Temporary contraindication

Decision Framework:

  • 0-1 risk factors (excluding prior VTE): Combination may be considered with close monitoring
  • 2+ risk factors: Strongly recommend against combination; explore alternatives
  • Prior VTE history: Do not combine - this is effectively a contraindication

Clinical Management if Combination is Necessary

If the clinical benefit justifies the risk:

  1. Optimize HRT formulation: Consider transdermal estrogen rather than oral (lower VTE risk with transdermal routes, though not studied specifically with JAK inhibitors) 3

  2. Use lowest effective doses: Femostan comes in various strengths; use the minimum dose controlling menopausal symptoms

  3. Monitor vigilantly for thrombotic symptoms:

    • Leg pain, swelling, warmth (DVT)
    • Chest pain, shortness of breath (PE)
    • Neurological symptoms (arterial thrombosis)

  4. Baseline and periodic laboratory monitoring per upadacitinib prescribing guidelines 2

  5. Patient education: Explicit counseling about VTE warning signs and when to seek emergency care

Alternative Approaches to Consider

For menopausal symptoms:

  • Non-hormonal options (SSRIs, gabapentin, clonidine)
  • Vaginal estrogen only (if symptoms are primarily genitourinary) - systemic absorption is minimal
  • Lifestyle modifications and behavioral interventions

For the underlying inflammatory condition:

  • If upadacitinib is for rheumatoid arthritis, consider biologics (TNF inhibitors, abatacept, tocilizumab) which don't carry the same VTE signal 1
  • If for other conditions, evaluate alternative JAK inhibitors or non-JAK therapies

Important Caveats

No pharmacokinetic interaction exists between upadacitinib and estrogen/progestins - a study demonstrated no effect on ethinylestradiol or levonorgestrel pharmacokinetics 4. The concern is purely pharmacodynamic (additive thrombotic risk), not drug-drug interaction.

The ACR reproductive health guidelines note that HRT should be avoided in patients with antiphospholipid antibodies due to thrombosis risk 3, establishing precedent for avoiding HRT in prothrombotic states - a principle that extends to JAK inhibitor use.

The combination is not absolutely contraindicated, but represents a high-risk scenario requiring careful patient selection, informed consent about increased VTE risk, and vigilant monitoring. In most cases, alternative management strategies for either the menopausal symptoms or the inflammatory condition should be explored first.

References

Related Questions

Is estradiol replacement therapy appropriate for a patient with a BRCA1 mutation who has had bilateral mastectomy and oophorectomy?
Can women with a family history of estrogen-receptor-positive breast cancer safely use hormone replacement therapy (HRT)?
Is a vaginal estradiol dose of 0.5 mg administered twice weekly considered a high dose for a post‑menopausal woman?
What is the appropriate estradiol dose to treat persistent hot flashes in a woman who is perimenopausal and continues to have symptoms after menopause?
What is the appropriate management for a 62‑year‑old postmenopausal woman with estrogen less than 30 pg/mL and progesterone less than 0.5 ng/mL?
What is the appropriate management for a pregnant woman who is Rh‑negative with a positive indirect Coombs test?
Is melatonin safe and appropriate for use in hepatic encephalopathy, and what dose is recommended?
Can Zosyn (piperacillin/tazobactam) cause Stevens‑Johnson syndrome?
How should a 72-year-old patient with an HbA1c of 6.6% be managed?
Can Stevens-Johnson syndrome be caused by Zosyn (piperacillin‑tazobactam), and which alternative antibiotic for cellulitis has minimal risk of Stevens-Johnson syndrome?
What is the appropriate propofol dosing regimen for sedation in a patient with advanced cirrhosis (Child‑Pugh B‑C) undergoing upper gastrointestinal endoscopy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.